The most common cause of thinning hair in women is female pattern hair loss, a hereditary condition that often begins in midlife. Shedding after childbirth or illness, thyroid problems and anemia can look similar, so diagnosis comes first.
The most common reason women notice thinning hair is female pattern hair loss (FPHL), a hereditary condition that the American Academy of Dermatology (AAD) says usually begins in a woman's 40s, 50s or 60s, though it can start earlier. It typically shows up as a widening part or a thinner ponytail rather than bald patches. Other causes, including shedding after childbirth or illness, thyroid disease and anemia, can look similar, which is why getting the right diagnosis is the first step. Treatment works best when started early, and the main options are topical minoxidil, which is FDA-approved for women, and off-label prescription medications such as spironolactone.
The AAD describes FPHL as hereditary, inherited from either or both parents, and notes that because it is more common after menopause, hormones may also play a role. It is progressive: without treatment, the part gets wider, hair near the temples may recede, and some women develop widespread thinning. A clinical review indexed in PubMed calls it the most common form of hair loss in women and notes that treatment is more effective at stopping progression than at regrowing hair that has already thinned, which is why early diagnosis matters.
Excessive shedding, called telogen effluvium, is common in women after specific events. The AAD notes that after giving birth, shedding usually starts about two months later and peaks around four months, and that hair generally regains its fullness within 6 to 9 months. Other triggers include high fever or illness, surgery, intense stress, losing 20 pounds or more and stopping birth control pills.
MedlinePlus lists anemia, thyroid disease, lupus, alopecia areata, scalp ringworm and certain medications among the causes of hair loss, along with tight hairstyles and continual hair pulling. The FDA labeling for women's minoxidil foam notes that it will not help hair loss related to pregnancy, very low body iron, excess vitamin A, recently stopping birth control pills, an underactive thyroid, chemotherapy or scarring scalp conditions. Those causes need their own evaluation and treatment.
MedlinePlus suggests seeing a provider if hair loss comes with acne, unwanted facial hair or irregular periods. The PubMed review notes that in women with signs of excess androgens, clinicians should look for ovarian or adrenal conditions.
According to the PubMed review, FPHL can usually be confirmed with a medical history and a scalp examination alone; a scalp biopsy can confirm it but is usually not needed. The AAD emphasizes ruling out other causes that look like FPHL, because each requires different treatment. Because anemia, low iron and thyroid disease can all contribute to hair loss, a clinician may check for them based on your history and symptoms.
| Option | Status for FPHL | What to know |
|---|---|---|
| Topical minoxidil 2% or 5% | FDA-approved, no prescription needed | AAD's most-recommended option; avoid in pregnancy and breastfeeding |
| Spironolactone tablets | Off-label | Prescription only; pregnancy must be avoided |
| Finasteride, dutasteride, flutamide | Off-label | Prescription only; not options during pregnancy |
| Laser devices, PRP, hair transplant | Varies | Evidence is still developing for lasers and PRP |
The AAD calls minoxidil the most-recommended treatment for FPHL and notes that both 2% and 5% products are FDA-approved for it. In a 48-week randomized trial of 381 women published in the Journal of the American Academy of Dermatology in 2004, 5% minoxidil was superior to placebo on all three main measures, including hair counts and both patient and investigator assessments of growth. The 2% solution beat placebo on hair counts and investigator ratings. Itching, irritation and unwanted facial hair were more common with the 5% strength.
The AAD notes that a temporary increase in shedding during the first 2 to 8 weeks is possible and stops as hair begins to regrow. Women should plan on about 6 to 12 months of continuous use before judging results, and the women's foam labeling suggests stopping and seeking advice if there is no regrowth by 6 months. The AAD advises women who are pregnant, planning pregnancy or breastfeeding to avoid minoxidil.
The AAD notes that spironolactone is FDA-approved for other conditions, not FPHL, but that dermatologists have prescribed it for hair loss for decades. Its FDA-approved uses, per its prescribing information, include heart failure, high blood pressure, certain kinds of fluid retention and a hormone disorder called primary hyperaldosteronism. The AAD reports studies suggesting it helps about 40 percent of women with FPHL; in one study of 166 women, 42 percent reported mild improvement and 31 percent reported increased thickness.
Two safety points stand out:
Spironolactone is available through NewDay Wellness as an oral tablet when a licensed provider determines it is appropriate.
The AAD notes that a dermatologist may prescribe finasteride, flutamide or dutasteride off-label, but that none of these prescription hair loss medications is an option for women who are pregnant or planning pregnancy. For devices and procedures, the AAD says FDA-approved home laser devices show some benefit in a few studies, PRP shows early promise but needs more research, and hair transplants can help some women with enough donor hair. In most studies, supplements such as biotin had no effect on hair growth.
In most cases, yes. The AAD describes postpartum shedding as temporary, peaking around four months after birth and generally returning to normal fullness within 6 to 9 months. If thinning continues beyond that, it is worth checking for other causes, including FPHL.
The AAD advises women who are breastfeeding to avoid minoxidil, because traces may pass into breast milk. Talk with a licensed provider about timing if you are nursing.
For both minoxidil and prescription medications, the AAD suggests about 6 to 12 months. It notes that if a prescription medication produces no growth within 12 months, it is unlikely to work for you.
The AAD notes that the hair gained with treatment is gradually lost after stopping; for prescription medications, this happens in about three to four months.
A licensed provider can review your history, medications and pregnancy plans, decide whether lab work makes sense and explain whether a topical, oral or combined approach fits your situation. Learn more on our Hair & Skin page or read about hair loss treatment categories. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
For pattern hair loss, the FDA has approved topical minoxidil and oral finasteride (men only). Spironolactone and oral minoxidil are used off-label, and compounded topical blends are not FDA-approved. Here is how the categories differ.
Read articleTopical minoxidil labels say results may appear at 2 to 4 months for men and 3 to 6 months for women, and the AAD suggests 6 to 12 months to judge. A brief shed early on is common, and benefits last only with continued use.
Read articleSpironolactone is a blood pressure medication that dermatologists prescribe off-label for hormonal acne in women. A 2023 trial found it improved acne more than placebo by 24 weeks. Pregnancy must be avoided, and potassium matters for some people.
Read article